Hima Kona, MD
Pulmonary Disease · Cookeville, TNNPI 1982800603
Payments from drug & device makers
Across 605 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$638
- Mylan Specialty L.p.$603
- Baxter Healthcare$547
- plus $3K from 30 others
What the payments were for
- Food & beverage$10,37498%
- Education$2642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 139 | $2,480 |
| GSK | 121 | $1,848 |
| Boehringer Ingelheim | 68 | $1,345 |
| Grifols USA, LLC | 40 | $638 |
| Mylan Specialty L.p. | 39 | $603 |
| Baxter Healthcare | 30 | $547 |
| Insmed, Inc. | 23 | $494 |
| Sanofi | 15 | $311 |
| Regeneron Healthcare Solutions, Inc. | 15 | $302 |
| Philips North America LLC | 20 | $297 |
| Sunovion Pharmaceuticals Inc. | 15 | $205 |
| United Therapeutics Corporation | 7 | $153 |
| Viatris Specialty LLC | 8 | $149 |
| Electromed, Inc. | 8 | $142 |
| Advanced Respiratory, Inc | 5 | $117 |
| Genentech USA, Inc. | 7 | $107 |
| Inspire Medical Systems, Inc. | 3 | $103 |
| Jazz Pharmaceuticals Inc. | 5 | $94 |
| Inogen, Inc. | 6 | $80 |
| Intuitive Surgical | 1 | $77 |
| Pulmonx Corporation | 4 | $61 |
| Novartis | 4 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Merck | 4 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Genentech, Inc. | 1 | $40 |
| Shire North American Group Inc | 2 | $34 |
| Verona Pharma, Inc. | 2 | $33 |
| Pfizer | 2 | $25 |
| Amgen | 1 | $25 |
| CMP Pharma, Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $20 |
| Covidien LP | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,639 in reported general payments places this provider in the 70th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 650 | $792,296 |
| Spiriva RespimatTiotropium Bromide | 232 | $233,306 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 170 | $199,914 |
| OfevNintedanib Esylate | 13 | $166,449 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $138,862 |
| Breo ElliptaFluticasone/Vilanterol | 170 | $124,455 |
| Pirfenidone | 13 | $76,845 |
| Dupixent PenDupilumab | 17 | $69,590 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 83 | $59,690 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $56,848 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 47 | $54,538 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 287 | $51,767 |
| EliquisApixaban | 46 | $41,963 |
| SymbicortBudesonide/Formoterol Fumarate | 114 | $39,779 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,176 | $37,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,848 | $1,004,347944 claims |
| Boehringer IngelheimSpiriva Respimat, Ofev, Stiolto Respimat, Combivent Respimat | $1,345 | $513,982375 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,480 | $256,530304 claims |
| Grifols USA, LLCProlastin C | $638 | $138,86212 claims |
| PfizerEliquis | $25 | $41,96346 claims |
| MerckDulera | $57 | $7,22014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Cookeville
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.